
ZURA Stock Forecast & Price Target
ZURA Analyst Ratings
Bulls say
Zura Bio is viewed favorably because tibulizumab still has meaningful upside in systemic sclerosis, where the biology is better validated and less noisy than hidradenitis suppurativa, with topline Phase II data on-track for 1H27. The company also has a third target in polymyalgia rheumatica, with a Phase 2 start by year-end 2026, a ~N=150-180 patient study, and a large addressable population of ~800k in the US and ~1MM in the EU. Financially, the outlook is supported by a cash position of $2/sh, while the programs are modeled to drive substantial future revenue potential, including 2035E worldwide sales of $1.6B for PMR and peak global revenues of $2.3B for SSc in 2036.
Bears say
Zura Bio is weighed down by tibulizumab’s Phase 2 failure in hidradenitis suppurativa, where the well-powered 247-patient study missed its primary and key secondary endpoints and led management to terminate the HS program, underscoring weak clinical execution risk. The setback is amplified by high placebo response rates and the need to now depend on later-stage readouts in other indications, while the company still faces regulatory, manufacturing, and reimbursement hurdles that could slow or block value creation. Given the stock’s roughly 71% decline versus the XBI’s 3.7% gain, investors are left with a company whose pipeline remains scientifically uncertain and whose commercial prospects remain highly speculative.
This aggregate rating is based on analysts' research of Zura Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.
ZURA Analyst Forecast & Price Prediction
Start investing in ZURA
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Zura Bio Ltd (ZURA) Forecast
ZURA Analyst Forecast & Price Prediction
Start investing in ZURA
Order type
Buy in
Order amount
Est. shares
0 shares